EmeTerm

EmeTerm sells FDA-cleared, wearable neuromodulation bands that stop nausea and vomiting caused by motion sickness, morning sickness, chemotherapy and VR use. The product line is one SKU—the anti-nausea wristband—priced at mid-range (≈ US $110–150) and sold direct-to-consumer through emeterm.com, Amazon, Walmart.com and a network of hospital supply distributors. The brand’s core IP is a pre-set 35 Hz electrical pulse delivered via integrated electrodes that target the median/P6 nerve without gels or wires; one 30-minute charge gives 7 hours of continuous therapy. Clinical data (five peer-reviewed studies) shows >85 % efficacy, giving EmeTerm credibility with oncologists, anesthesiologists and airlines that stock the device for crew and passengers. Primary buyers are pregnant women avoiding drugs, cruise and air travelers, VR gamers, and chemo patients seeking non-pharmacological relief; they value drug-free, side-effect-free control that can be reused unlimited times. The brand voice is medical-grade yet consumer-friendly, emphasizing empowerment, mobility and “enjoy the journey” messaging. EmeTerm competes against acupressure elastic bands, generic TENS wrist units and prescription anti-emetics; it differentiates through FDA-clearance, dedicated nausea-specific waveform, no skin prep, airline-approved lithium battery, and a 30-day money-back guarantee backed by U.S. customer support.